

Basic research in renal tumours: Gene profiling and molecular markers

Poster Session 18

Saturday, 12 March
16:00 - 17:30

Location: Room 14c (ICM, Level 1)

Chairs: L. Mengual, Barcelona (ES)
A. Vuksanovic, Belgrade (RS)

Aims and objectives of this presentation

To show and discuss latest advances in gene profiling as well as molecular markers of prognosis.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 217 **Identifying the metastatic subclone by exhaustive sampling of primary and metastasis in clear cell renal cell carcinoma (ccRCC) pair**
By: [Soultati A.](#)¹, O'Brien T.², Challacombe B.J.², Nicol D.³, Horswell S.⁴, Xu H.⁵, Rowan A.J.⁵, Lopez J.I.⁶, Stares M.⁵, Chandra A.⁷, Chowdhury S.⁸, Rudman S.⁸, Matthews N.⁹, Larkin J.¹⁰, Turajlic S.⁵, Swanton C.⁵
Institutes:¹Guy's and St' Thomas NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, ²Guy's and St' Thomas NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴The Francis Crick Institute, Dept. of Bioinformatics and Biostatistics, London, United Kingdom, ⁵The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ⁶Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, ⁷Guy's and St' Thomas NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁸Guy's and St' Thomas NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁹The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom, ¹⁰Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom
- 218 **Intermittent hypoxia increases tumor angiogenesis in a mouse model of kidney cancer**
By: [Vilaseca Cabo A.](#)¹, Musquera M.¹, Torres M.², Campillo N.², Gozal D.³, Montserrat J.⁴, Touijer K.⁵, Farré R.², Almendros I.², Alcaraz A.¹
Institutes:¹Hospital Clínic De Barcelona, Dept. of Urology, Barcelona, Spain, ²Universitat De Barcelona, Dept. of Biophysics and Bioengineering, Barcelona, Spain, ³University of Chicago, Dept. of Sleep Disorders, Chicago, United States of America, ⁴Hospital Clínic De Barcelona, Dept. of Pneumology, Barcelona, Spain, ⁵Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America
- 219 **Quantification, culture and characterization of circulating endothelial progenitor cells in patients with renal cell carcinoma**
By: [Yang B.](#), Gu W., Sun W., Guo C., Yao X., Zheng J.
Institutes:Shanghai Tenth People's Hospital, Tongji University School Of Medicine, Dept. of Urology, Shanghai, China
- 220 **Tumour-derived vascular endothelial growth factor mobilizes circulating endothelial progenitor cells and contributes to vasculogenesis of renal cell carcinoma**
By: [Yang B.](#), Gu W., Guo C., Sun W., Che J., Liu M., Yao X., Zheng J.
Institutes:Shanghai Tenth People's Hospital, Tongji University School of Medicine, Dept. of Urology, Shanghai, China
- 221 **Multi-region whole exome sequencing reveals monoclonal nature of inferior vena cava tumour thrombus extension in clear cell renal cell carcinoma**

By: Stares M.¹, Nicol D.², O'Brien T.³, Challacombe B.³, Rowan A.¹, Horswell S.⁴, Salm M.⁴, Soutati A.⁵, Hazell S.⁶, Chandra A.⁷, López J.⁸, Fisher R.⁹, Chowdhury S.⁵, Rudman S.⁵, Gore M.⁹, Larkin J.⁹, Matthews N.¹⁰, Turajlic S.¹, Swanton C.¹

Institutes:¹The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ²Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴The Francis Crick Institute, Dept. of Bioinformatics and Biostatistics, London, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ⁶Royal Marsden Hospital NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁷Guy's and St Thomas' NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁸Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, ⁹Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ¹⁰The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom

222

Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells is associated with poor prognosis in clear cell renal cell carcinoma

By: Füssel S.¹, Toma M.², Erdmann K.¹, Wehner R.³, Kloß A.³, Baretton G.², Wirth M.P.¹, Schmitz M.³

Institutes:¹Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Urology, Dresden, Germany, ²Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Pathology, Dresden, Germany, ³Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Immunology, Dresden, Germany

223

Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma

By: Wan F., Ma C., Zhang H., Shi G., Zhu Y., Ye D.

Institutes:Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

224

Genetic alterations in specific chromosomal regions indicate metastatic potential in ccRCC patients

By: Grimm J.¹, Janssen M.¹, Hartmann A.², Kunath F.³, Stöhr C.², Stöckle M.¹, Junker K.¹

Institutes:¹UKS Universitätsklinikum des Saarlandes, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, ²University Hospital Erlangen, Dept. of Pathology, Erlangen, Germany, ³University Hospital Erlangen, Dept. of Urology, Erlangen, Germany

225

Identification and validation of an 8-gene expression signature for predicting high Fuhrman grade renal cell carcinoma

By: Wan F.¹, Zhu Y.², Han C.², Xu Q.³, Zhang H.², Shi G.², Gu W.², Ye D.²

Institutes:¹Shanghai Medical College, Fudan University, Dept. of Oncology, Shanghai, China, ²Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ³Fudan University Shanghai Cancer Center, Dept. of Pathology, Shanghai, China

226

Myopodin methylation correlates to tumour progression and predicts antiangiogenic response in kidney cancer

By: Perez-Lonzac A.², Pompas-Veganzones N.², Beltran M.³, Beardo P.⁴, Vazquez F.⁵, Cozar J.M.⁵, Alvarez-Ossorio J.L.⁶, Sanchez-Carbayo M.¹

Institutes:¹University of the Basque Country, Bladder Cancer Group, Vitoria-Gasteiz, Spain, ²University of the Basque Country, Translational Oncology Lab, Vitoria-Gasteiz, Spain, ³Hospital Puerta Del Mar, Dept. of Pathology, Cadiz, Spain, ⁴Hospital De Jerez, Dept. of Urology, Cadiz, Spain, ⁵Hospital Virgen De Las Nieves, Dept. of Urology, Cadiz, Spain, ⁶Hospital Puerta Del Mar, Dept. of Urology, Cadiz, Spain

227

Circulating free genomic and mitochondrial DNA fragments and their diagnostic and prognostic potential in clear cell renal cell carcinoma patients

By: Ralla B.¹, Hongbiao L.¹, Jung M.¹, Rabenhorst S.¹, Kilic E.¹, Budach N.², Fendler A.¹, Jung K.¹, Busch J.¹

Institutes:¹Charité - Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ²Charité - Universitätsmedizin Berlin, Dept. of Radiology, Berlin, Germany

228

Predictive molecular biomarkers of renal clear cell carcinoma

By: Trevisani F.¹, Cascione L.², Ghidini M.³, Lampis A.⁴, Fassan M.⁵, Hanhe J.K.⁴, Dell'Antonia G.⁶, Rigotti P.⁷, Larcher A.¹, Capitanio U.¹, Benigni F.¹, Briganti A.¹, Bertini R.¹, Salonia A.¹, Montorsi F.¹, Valeri N.⁴

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology, Department of Urology, URI, Milan, Italy, ²IOR - Institute of Oncology Research, Lymphoma and Genomics Research Program Bioinformatics Core Unit, Bellinzona, Switzerland, ³Hospital of Cremona, Dept. of Oncology, Cremona, Italy, ⁴Institute of Cancer Research, Laboratory of Gastrointestinal Cancer Biology and Genomics, London, United Kingdom, ⁵University of Padua, Dept. of Pathology, Padua, Italy, ⁶IRCCS Ospedale San Raffaele, Division of Pathology, Milan, Italy, ⁷University of Padua, Dept. of Surgical Science, Milan, Italy

229

Significance of TERT variants in renal cell carcinoma

By: Casuscelli J.¹, Manley B.¹, Redzematovic A.¹, Becerra M.¹, Tennenbaum D.¹, Arcila M.¹, Voss M.², Feldman D.², Motzer R.², Coleman J.³, Russo P.³, Hsieh J.¹, Hakimi A.A.³

Institutes:¹Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York City, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York City, United States of America, ³Memorial Sloan Kettering Cancer Center, Dept. of Surgery, New York City, United States of America

230

Blood based exosomal miRNAs as biomarkers for diagnosis and prognosis of clear cell renal cell cancer

By: Heinzelmann J.¹, Baumgart S.², Hoelters S.², Janssen M.², Stöckle M.², Junker K.²

Institutes:¹Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Hamburg, Germany, ²Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg, Germany